2023 World Conference on Lung Cancer (Posters)-EP10.01. A Phase 1/2 Study of REGN5093-M114, a METxMET Antibody-Drug Conjugate, in Patients with MET-Overexpressing NSCLC

EP10.01. A Phase 1/2 Study of REGN5093-M114, a METxMET Antibody-Drug Conjugate, in Patients with MET-Overexpressing NSCLC - PDF(Abstract)

Back to course

Pdf Summary

This abstract is about a phase 1/2 study of a new drug called REGN5093-M114 in patients with metastatic non-small cell lung cancer (NSCLC) that overexpresses the protein called mesenchymal epithelial transition factor (MET). MET is commonly overexpressed in several types of cancers, including NSCLC. REGN5093-M114 is an antibody-drug conjugate that specifically targets MET. In preclinical studies, REGN5093-M114 showed significant anti-tumor activity in MET-overexpressing cancers.<br /><br />The study is an open-label, multicenter trial that aims to evaluate the safety, tolerability, pharmacokinetics (PK), maximum tolerated dose, and anti-tumor activity of REGN5093-M114. Eligible patients must have advanced stage NSCLC with MET overexpression confirmed by immunohistochemistry. The drug will be administered intravenously every 3 weeks until disease progression or intolerable side effects.<br /><br />The primary objectives of the study are to determine the safety, PK, and recommended dosing regimen of REGN5093-M114. The secondary objectives include evaluating treatment durability and the immunogenicity of the drug. The study is currently enrolling patients, and as of March 30, 2023, 17 patients have been enrolled across different dose levels.<br /><br />The results of the study are not mentioned in this abstract, and no conclusions are provided. The keywords associated with this study are non-small cell lung cancer, bispecific, and mesenchymal epithelial transition factor.<br /><br />This abstract belongs to the track of metastatic non-small cell lung cancer - immunotherapy and is classified as a regular abstract.

Asset Subtitle

Alexander Drilon

Meta Tag

Speaker Alexander Drilon

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

REGN5093-M114

metastatic non-small cell lung cancer

NSCLC

mesenchymal epithelial transition factor

MET

antibody-drug conjugate

preclinical studies

safety

pharmacokinetics

recommended dosing regimen